Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.
about
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndromeReduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic reviewThe histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis.Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and muTherapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patientsSafety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipientsMinimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant.Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia.Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.Complications of allogeneic hematopoietic stem cell transplantation.A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population.Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant.Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation.Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children.Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.Allo-SCT using BU, CY and melphalan for children with AML in second CR.
P2860
Q27024786-10F01589-0177-4BB9-9EB4-5723FF3E7476Q34770016-E0F35911-35ED-4644-8D6F-8219CD593EB1Q35060679-CB66B527-DEF5-4A86-BFDB-544D266431F0Q35085078-1217FFB2-0F0F-42DF-A3AF-560DC11B006BQ36182610-5BBB6E73-8EC9-4A90-9DD9-380A36285B5AQ36341861-7D3CA5DE-730E-4706-91CF-C4C08868BC89Q36608468-610A24B7-3A14-4E3E-995D-F50215FEC744Q36703516-8E081CA8-D5B9-46AF-B07C-D940B0775BD6Q36742108-DB56F029-9B48-491D-9F2C-D75F75561862Q36768621-450CCEE6-771F-465C-B2CF-FAA127614355Q37070285-582E13A3-5167-4D2E-81E1-069E3FF94E32Q37258220-9D2A86C2-8B6A-4BFE-9A42-D1132B20834EQ37942816-2634A0D6-F8D7-4A6D-ABE6-AADEA5F9860DQ38025158-0DD58BF7-E31B-48D2-8EC2-4B79FD18092AQ38133244-C44F9976-BB81-4DBE-B63A-77CCFAB8A33FQ38217938-9FB73DFA-37E6-4ADE-AFAC-0460F33B8907Q39041930-E50262C0-434F-4587-B10B-58FCF5C613BCQ44801887-BC1E2BA3-035F-4548-8777-61DBEF0042D0Q50924228-5A093D5B-6474-40F8-AC91-920F1846A669Q52613271-C28119E1-27C3-4F96-9586-A99CCBC4D8DFQ53038103-DB2ADC29-D867-4A21-97CB-0B5FB07F9ADEQ53108503-63FCB60B-D36A-43BB-B36B-A1A982A65CC0
P2860
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacokinetic targeting of i ...... or acute myelogenous leukemia.
@ast
Pharmacokinetic targeting of i ...... or acute myelogenous leukemia.
@en
Pharmacokinetic targeting of i ...... or acute myelogenous leukemia.
@nl
type
label
Pharmacokinetic targeting of i ...... or acute myelogenous leukemia.
@ast
Pharmacokinetic targeting of i ...... or acute myelogenous leukemia.
@en
Pharmacokinetic targeting of i ...... or acute myelogenous leukemia.
@nl
prefLabel
Pharmacokinetic targeting of i ...... or acute myelogenous leukemia.
@ast
Pharmacokinetic targeting of i ...... or acute myelogenous leukemia.
@en
Pharmacokinetic targeting of i ...... or acute myelogenous leukemia.
@nl
P2093
P2860
P356
P1476
Pharmacokinetic targeting of i ...... or acute myelogenous leukemia.
@en
P2093
Claudio Anasetti
Hugo F Fernandez
Janelle Perkins
Jongphil Kim
Joseph Pidala
Mohamed A Kharfan-Dabaja
Taiga Nishihori
Teresa Field
P2860
P2888
P356
10.1186/1756-8722-3-36
P577
2010-10-06T00:00:00Z
P5875
P6179
1002365000